A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.

about

A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.

Item

http://www.wikidata.org/entity/Q48018366

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

A population-based study of ce ...... arge B-cell lymphoma patients.

@en

A population-based study of ce ...... arge B-cell lymphoma patients.

@nl

type

Item

label

A population-based study of ce ...... arge B-cell lymphoma patients.

@en

A population-based study of ce ...... arge B-cell lymphoma patients.

@nl

prefLabel

A population-based study of ce ...... arge B-cell lymphoma patients.

@en

A population-based study of ce ...... arge B-cell lymphoma patients.

@nl

P1476

A population-based study of ce ...... arge B-cell lymphoma patients.

@en

P2093

Gunilla Enblad

http://www.w3.org/2001/XMLSchema#string

Gustaf Hedström

http://www.w3.org/2001/XMLSchema#string

Johanna Triumf

http://www.w3.org/2001/XMLSchema#string

Mattias Berglund

http://www.w3.org/2001/XMLSchema#string

Maysaa Abdulla

http://www.w3.org/2001/XMLSchema#string

Rose-Marie Amini

http://www.w3.org/2001/XMLSchema#string

Sofia Laszlo

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification

P304

1126-1131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/0284186X.2016.1189093

http://www.w3.org/2001/XMLSchema#string

P433

9-10

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27549735

http://www.w3.org/2001/XMLSchema#string